Warning Letter — Excelvision - Fareva
The FDA Center for Drug Evaluation and Research issued a Warning Letter to Excelvision - Fareva following an inspection of their facility.
The letter specifically addresses Excelvision - Fareva and potentially impacts pharmaceutical manufacturers utilizing their contract manufacturing services.
A Warning Letter from CDER signifies that the FDA found significant violations of Current Good Manufacturing Practice (CGMP) regulations. This may lead to the withholding of new product approvals or the restriction of importation into the United States if the facility is located abroad. The source suggests a breakdown in the quality management system that requires formal remediation.
Quality and Compliance departments should review recent inspectional findings (Form 483) and ensure that all systemic gaps identified during the site audit are addressed with robust, evidence-based corrective actions. Regulatory teams should assess the impact of this letter on pending applications or certificates of pharmaceutical product.
FDA Warning Letter issued to: Excelvision - Fareva. 06/25/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/excelvision-726714-fareva
Open in openFDA / FDA.gov